Zometa is owned by Novartis.
Zometa contains Zoledronic Acid.
Zometa has a total of 3 drug patents out of which 0 drug patents have expired.
Zometa was authorised for market use on 20 August, 2001.
Zometa is available in injectable;intravenous dosage forms.
Zometa can be used as multiple myeloma; bone metastases; hypercalcemia of malignancy.
The generics of Zometa are possible to be released after 05 February, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8324189||NOVARTIS||Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases|| |
(1 year, 11 months from now)
|NOVARTIS||Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases|| |
(2 years from now)
|US7932241||NOVARTIS||Pharmaceutical products comprising bisphosphonates|| |
(4 years from now)
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 20 August, 2001
Treatment: Multiple myeloma; Bone metastases; Hypercalcemia of malignancy
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic